Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425683 | 0.86 | — | — | |
| SCHEMBL169778 | 0.79 | — | — | |
| SCHEMBL12372506 | 0.79 | — | — | |
| SCHEMBL1667760 | 0.76 | — | — | |
| SCHEMBL1667836 | 0.73 | — | — | |
| SCHEMBL1667834 | 0.73 | — | — | |
| SCHEMBL2236435 | 0.72 | — | — | |
| SCHEMBL1809810 | 0.72 | L3MBTL1 (0.32) | GAAL3MBTL1KMT2A | |
| SCHEMBL1565394 | 0.72 | — | — | |
| SCHEMBL13939240 | 0.71 | GAA (0.31) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230799-A2 | CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025226895-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS COMPRISING SUBSTITUTED OR MODIFIED DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONES | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025226887-A1 | DIAMINOMETHYLENE-CONTAINING AGONISTS OF THE PARATHYROID HORMONE 1 RECEPTOR | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024091498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-9000188-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000188-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000188-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2309860-B1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | DARTMOUTH COLLEGE (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8314137-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTESS OF DARTMOUTH COLLEGE (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314137-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTESS OF DARTMOUTH COLLEGE (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314137-B2 | Monocyclic cyanoenones and methods of use thereof | TRUSTESS OF DARTMOUTH COLLEGE (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-11 | — | — | US | disclosed |
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-11 | — | — | US | disclosed |
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-11 | — | — | US | disclosed |
| EP-2309860-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | Trustees of Dartmouth College (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011782-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196007-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | HSD17B7, HSD17B12, CYP11B2 | GAA 3846/4885L3MBTL1 3356/4885KMT2A 3321/4885 |
| US-20130274480-A1 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF | HSD17B7, HSD17B12, CYP11B2 | GAA 3846/4885L3MBTL1 3356/4885KMT2A 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.